AI주식인사이트AI Stock Insight
C

일동홀딩스

000230KOSPI의약품 제조업

51.5 / 100

Reference Date: 2026-07-24

Financial Score24.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 1.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Iljung Holdings operates seven business divisions, including pharmaceuticals, advertising, ion water generators, software and medical devices, functional foods, and clinical pharmacology consulting. The company's main revenue comes from pharmaceutical manufacturing and sales (614.94 billion won) and software/medical device development (27.99 billion won), while advertising and ion water generator segments experienced declines compared to the previous year.

Number of Employees

84people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
3.30Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR
0.21Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE
7.20Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio
40.61Industry Average 12.430.0Point

3.3x industry avg (risky)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼3.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲407.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -12.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 6,170Won52-week high 15,81052-week low 5,710
1-month return3.0Point

1m -1.12% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-07-16